About bevacizuma b
Vascular endothelial growth factor inhibitor
Used for
- Treats certain cancers, including colorectal, lung, kidney, ovarian, and cervical cancers.
- Often used with other anticancer medicines.
Usual adult dose
Usually 5–15 mg/kg by intravenous infusion every 2–3 weeks, depending on cancer and treatment regimen.
Common side effects
- High blood pressure
- Bleeding or blood clots
- Protein in urine
- Slow wound healing
Important warnings
- Can cause serious bleeding, bowel perforation, blood clots, or severe high blood pressure.
- May impair wound healing; treatment is usually stopped before and after major surgery.
- Monitor blood pressure and urine protein during treatment.
- Given by intravenous infusion under specialist supervision.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for at least six months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least six months after the last dose.
Interactions
- Anticoagulants and antiplatelet medicines may increase bleeding risk.
- Other anticancer medicines can add to toxicity, depending on the regimen.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.